Craig-Hallum initiated coverage of Myriad Genetics (MYGN) with a Buy rating and $29 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing ...

Myriad Genetics (MYGN) and INTERLINK Care Management announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital, Baylor Genetics and collaborating institutions provided ...

Neurogeneticists at the University of Florida led by Lien Nguyen, Ph.D., and Laura Ranum, Ph.D., have discovered a novel genetic mutation and associated buildup of toxic proteins in the brain - a ...

Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by AI-driven... Datar Cancer Genetics (DCG) today announced the ...

BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine ...

The test evaluates the effectiveness or resistance of chemotherapy drugs through direct observation of their action on tumor cells. It personalizes treatment ...

More than 80% of all genetic research is conducted in individuals of European ancestry 1, raising concerns that Indigenous people and other under-represented groups might not benefit from the ...

-Datar Cancer Genetics presenta un revolucionario análisis de sangre informado basado en el tumor para el control de enfermedades residuales El análisis de sangre Target-MRD utiliza una ...

GeneDx has a big market in mind for its genetic testing: every newborn baby. The 24-year-old-company wants to make the testing common at birth. The goal: Identify potential diseases or conditions ...